Xenograft GVHD

Description

Differential response to Graft versus Host Disease (GVHD) induction can be observed in animals sourced from different vendors, some of which are mediated by vendor-differences in microbiome. Evaluation of GVHD phenotypes in animals sourced from different vendors can be a straightforward approach to assess the microbiome’s impact in a given GVHD mode or with respect to your novel therapeutic approach. Data from the xenograft GVHD model induced in animals from different vendors is shown.

Model Systems
  • huPBMCs (donor) → NSG Mice (host)
Standard Readouts
  • Survival
  • Percent weight change
  • Engraftment assessment
  • GVHD score
  • Diarrhea and blood in stool incidence
  • Plasma/serum cytokines
  • Terminal histopathology and/or IHC analyses
Additional Readouts
  • Engraftment assessment
  • Peripheral blood/lymphoid organ immunophenotyping
  • Endoscopy colitis scoring
  • Terminal tissue weights and measurement
  • Bacterial load (culture/qPCR)
  • Sequencing and metagenomics
  • Terminal colon weight and length measurement
  • Custom assays
Representative DataClick Image to Enlarge
Percent Weight Change in the xGVHD Model Between Animal Vendors

xGVHD animals are weighed daily, and body weight change as compared to Day 0 is calculated. The AUC is calculated to compare treatment arms and is shown in the inset. (****p<0.001).

GVHD Score in the xGVHD Model Between Vendors

xGVHD animals are evaluated daily for weight loss, posture, activity, fur texture, and skin integrity phenotypes. Each phenotype is scored and used calculate a GVHD score. The AUC is calculated to compare groups and is shown in the inset. (***p<0.005; ****p<0.001).

Survival the xGVHD Model Between Animal Vendors

Animals are evaluated for survival and moribundity on a daily basis.

Human Cell Engraftment in the xGVHD Model

Animals are monitored for human leukocyte engraftment via flow cytometry over time. (**p<0.01; ***p<0.005; ****p<0.001).

Daniel Lichtman

Managing Partner